Kalvista Pharmaceuticals Inc

NASDAQ KALV

Data sourced from

and

Download Data

Kalvista Pharmaceuticals Inc Current Assets to Total Assets Ratio 2 year CAGR for the Trailing 12 Months (TTM) ending January 31, 2024: -2.58%

Kalvista Pharmaceuticals Inc Current Assets to Total Assets Ratio 2 year CAGR is -2.58% for the Trailing 12 Months (TTM) ending January 31, 2024, a -245.94% change year over year. The current assets to total assets ratio measures the proportion of a company's current assets in relation to its total assets. It is calculated by dividing current assets by total assets. This ratio indicates the percentage of a company's total assets that are in the form of current assets, such as cash, receivables, and inventory. It provides insights into the company's liquidity and the extent to which its assets are readily convertible to cash in the short term. CAGR, or the Compound Annual Growth Rate, quantifies the mean annual growth rate of an investment or financial metric over a specified time span, considering the influence of compounding. It is instrumental in determining the true annualized return on an investment.

Kalvista Pharmaceuticals Inc Current Assets to Total Assets Ratio for the Trailing 12 Months (TTM) ending January 31, 2023 was 0.94, a -2.41% change year over year.
Kalvista Pharmaceuticals Inc Current Assets to Total Assets Ratio for the Trailing 12 Months (TTM) ending January 31, 2022 was 0.96, a 0.94% change year over year.
Kalvista Pharmaceuticals Inc Current Assets to Total Assets Ratio for the Trailing 12 Months (TTM) ending January 31, 2021 was 0.95, a -1.39% change year over year.
Kalvista Pharmaceuticals Inc Current Assets to Total Assets Ratio for the Trailing 12 Months (TTM) ending January 31, 2020 was 0.97, a -0.49% change year over year.

NASDAQ: KALV

Kalvista Pharmaceuticals Inc

CEO	Mr. Thomas Andrew Crockett M.B.A.
IPO Date	April 9, 2015
Location	United States
Headquarters	55 Cambridge Parkway, Cambridge, MA, United States, 02142
Employees	118
Sector	Healthcare
Industry	Biotechnology

Description

KalVista Pharmaceuticals, Inc., a clinical stage pharmaceutical company, engages in the discovery, development, and commercialization of small molecule protease inhibitors for diseases with unmet needs in the United States. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors. Its products include sebetralstat, which is initiation of the Phase 3 KONFIDENT trial as a potential oral, on-demand therapy for HAE attacks; and Factor XIIa, an oral inhibitor program which is in preclinical stage targets an enzyme in HAE. The company is headquartered in Cambridge, Massachusetts.

Key trends